Search Results - Yasumizu, Yota, M.D

  • Showing 1 - 3 results of 3
Refine Results
  1. 1
    Prognostic value of neutrophil-to-lymphocyte ratio in patients with metastatic renal cell carcinoma treated with first-line and subsequent second-line targeted therapy: A proposal of the modified-IMDC risk model

    Prognostic value of neutrophil-to-lymphocyte ratio in patients with metastatic renal cell carcinoma treated with first-line and subsequent second-line targeted therapy: A proposal... by Tanaka, Nobuyuki, M.D., Ph.D, Mizuno, Ryuichi, M.D., Ph.D, Yasumizu, Yota, M.D, Ito, Keiichi, M.D., Ph.D, Shirotake, Suguru, M.D., Ph.D, Masunaga, Ayako, M.D, Ito, Yujiro, M.D, Miyazaki, Yasumasa, M.D, Hagiwara, Masayuki, M.D, Kanao, Kent, M.D., Ph.D, Mikami, Shuji, M.D., Ph.D, Nakagawa, Ken, M.D., Ph.D, Momma, Tetsuo, M.D., Ph.D, Masuda, Takeshi, M.D, Asano, Tomohiko, M.D., Ph.D, Oyama, Masafumi, M.D., Ph.D, Oya, Mototsugu, M.D., Ph.D

    Published in Urologic oncology
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Effect of reclassification of the IMDC model in patients with metastatic renal cell carcinoma treated with targeted therapy in the first-line and second-line settings

    Effect of reclassification of the IMDC model in patients with metastatic renal cell carcinoma treated with targeted therapy in the first-line and second-line settings by Tanaka, Nobuyuki, M.D., Ph.D, Mizuno, Ryuichi, M.D., Ph.D, Shirotake, Suguru, M.D., Ph.D, Ito, Keiichi, M.D., Ph.D, Yasumizu, Yota, M.D, Masunaga, Ayako, M.D, Ito, Yujiro, M.D, Miyazaki, Yasumasa, M.D, Hagiwara, Masayuki, M.D, Kanao, Kent, M.D., Ph.D, Mikami, Shuji, M.D., Ph.D, Nakagawa, Ken, M.D., Ph.D, Momma, Tetsuo, M.D., Ph.D, Masuda, Takeshi, M.D, Asano, Tomohiko, M.D., Ph.D, Oyama, Masafumi, M.D., Ph.D, Oya, Mototsugu, M.D., Ph.D

    Published in Urologic oncology
    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  3. 3
    Impact of second-line targeted therapy dose intensity on metastatic renal cell carcinoma patients

    Impact of second-line targeted therapy dose intensity on metastatic renal cell carcinoma patients by Shirotake, Suguru, M.D., Ph.D, Yasumizu, Yota, M.D, Ito, Keiichi, M.D., Ph.D, Masunaga, Ayako, M.D, Ito, Yujiro, M.D, Miyazaki, Yasumasa, M.D, Hagiwara, Masayuki, M.D, Kanao, Kent, M.D., Ph.D, Mikami, Shuji, M.D., Ph.D, Nakagawa, Ken, M.D., Ph.D, Momma, Tetsuo, M.D., Ph.D, Masuda, Takeshi, M.D, Asano, Tomohiko, M.D., Ph.D, Oyama, Masafumi, M.D., Ph.D, Tanaka, Nobuyuki, M.D., Ph.D, Mizuno, Ryuichi, M.D., Ph.D, Oya, Mototsugu, M.D., Ph.D

    Get full text
    Article
    Save to List
    Saved in:

Search Tools: